Stereotactic Ablative Radiotherapy (SABR) for Hepatocellular Carcinoma (Adults)

Overview

NHS England has launched a four week consultation on a policy proposition for the use Stereotactic Ablative Radiotherapy (SABR) for the treatment of hepatocellular carcinoma (Adults).

The policy proposition has been developed in line with the findings of NHS England's SABR Commissioning through Evaluation (CtE) Programme, and after reviewing the evidence, NHS England are proposing to consider this treatment for routine commissioning.

The draft CtE report for the use of SABR in the treatment of hepatocellular carcinoma (Adults) can be found below.

The final report will be published on NHS England's website in the near future.

Related documents

• Policy proposition
• Evidence review
• Impact assessment report
• CPAG summary report
• Commissioning through Evaluation report
• Clinical panel report